Sensible, informed debate can ensure vaccines deliver on their huge promise, experts agree

3 May 2016

By Guy Martin

Stopping society from becoming complacent and confused over the value of vaccinations is crucial if they are to save more lives in future.

That is the agreed view of representatives of government, big pharma, trade groups, academia and research groups whose voices are being brought together by the Association of the British Pharmaceutical (ABPI) Vaccine Group, which advocates on industry’s behalf on the benefits of immunization and comprises staff from pharma companies including the UK’s AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK), the USA’s Pfizer (NYSE: PFE) and Japanese Takeda (TYO: 4502).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK